IDYA

#1519
IDEAYA Biosciences, Inc. - Common Stock
39.3 8 USD
-0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
39.38
40.16
Intervallo Annuale
26.81
42.68
Variazione giornaliera
-1.80%
Variazione Mensile
+11.02%
Variazione di 6 mesi
+23.80%
Variazione Annuale
+20.87%
Chiusura Precedente
40.1 0
Open
39.8 5
Minimo
39.3 8
Massimo
40.1 6
Volume
101
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
IDEAYA Biosciences, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
IDEAYA Biosciences, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IDEAYA Biosciences, Inc. current report, Q2 FY2026
8-K

IDEAYA Biosciences, Inc. current report, Q4 FY2025

Full document

Business Context and Reporting Period

This Form 8-K was filed by IDEAYA Biosciences, Inc. on December 5, 2025, reporting an event that occurred on December 4, 2025. The filing addresses a significant change in the company's strategic partnerships regarding its clinical development programs.

Key Financial Metrics

The filing does not provide specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. However, management explicitly stated that the company's expectation of a cash runway extending into 2030 remains unchanged following the reported event.

Material Changes

  • Termination of Collaboration: GlaxoSmithKline Intellectual Property (No. 4) ("GSK") elected to terminate the Collaboration, Option and License Agreement dated June 15, 2020.
  • Effective Date: The termination will become effective 90 days after the written notice date (December 4, 2025).
  • Program Transfer: During the 90-day transition period, GSK will transfer the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs back to IDEAYA Biosciences.

Guidance, Outlook, and Risks

Outlook and Strategy: The Company plans to evaluate strategic options for the IDE275 and IDE705 programs in 2026. Management confirmed that this termination does not alter the previously communicated cash runway guidance into 2030.

Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks cited include uncertainties in the drug development process, the early stage of the programs, regulatory approval timelines, manufacturing challenges, and the sufficiency of existing cash to fund operations.

Investor Verification Checklist

  • Verify the specific terms of the 90-day transition period for the transfer of IDE275 and IDE705 programs.
  • Confirm the financial impact of regaining full control of these programs versus the previous collaboration model.
  • Review the Company's 2025 Form 10-K for detailed risk factors regarding cash sufficiency and drug development timelines.
  • Monitor future announcements in 2026 regarding the strategic decisions made for the two transferred clinical programs.

Notizie